Selective estrogen receptor modulators and risk for coronary heart disease

Climacteric

Volumn 10, Issue 2, 2007, Pages 97-111

  Cano, A ^a,c   Hermenegildo, C ^b   Oviedo, P ^a   Tarin J J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Atherosclerosis; Coronary heart disease; Estrogens; Serms; Thrombosis

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ARZOXIFENE; BAZEDOXIFENE; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; CENTCHROMAN; CLOMIFENE; CONJUGATED ESTROGEN; DROLOXIFENE; ESTRADIOL; ESTROGEN; FULVESTRANT; IDOXIFENE; INDOLE DERIVATIVE; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; MIPROXIFENE PHOSPHATE; NAPHTHALENE DERIVATIVE; OSPEMIFENE; PIPENDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIOXIFENE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; BREAST CANCER; CARDIOVASCULAR DISEASE; ENDOTHELIUM; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; ESTROGENS; HEMOSTASIS; HUMANS; LIPIDS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33947593767     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701258804     Document Type: Review

References (121)

1. American Heart Association (http://www.americanheart.org)
2. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics, 2005 edn. European Heart Network and British Heart Foundation. http://www.ehnheart.org/files/ statistics%202005-092711A.pdf
3. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
5. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
7. Cano A, Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update 2000;6:207-11
8. Sanz-Gonzalez SM, Cano A, Valverde MA, Hermenegildo C, Andres V. Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2004;2:107-22
9. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-53
10. Cano A. Estrogen receptor modulation. In Filicori M, ed. Updates in Infertility Treatment. Bologna, Italy: Medimond, 2004:265-80
11. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65
12. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002;295:505-8
13. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA. Update on estrogen signaling. FEBS Lett 2003;546:17-24
14. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003;206:13-22
15. Muthyala RS, Sheng S, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem 2003;46:1589-602
16. Ghosh U, Ganessunker D, Sattigeri VJ, et al. Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. Bioorg Med Chem 2003;11:629-57
17. Shibata H, Spencer TE, Onãte SA, et al. Role of co-activators and co-repressors in the mechanism of steroid-thyroid receptor action. Rec Prog Horm Res 1997;52:141-65
18. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-72
19. Kousteni S, Han L, Chen JR, et al. Kinasemediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003;111:1651-64
20. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003;100:4807-12
21. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000;74:337-43
22. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002;90(1A):3-6F
23. Marin F, Barbancho MC. Clinical Pharmacology of selective estrogen receptor modulators (SERMs). In Cano A, Calaf i Alsina J, Duenas-Diez JL, eds. Selective Estrogen Receptor Modulators. New Brand of Multitarget Drugs. Berlin, Germany: Springer, 2006:49-69
24. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
25. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
26. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002;105:1368-73
27. Simoncini T, Varone G, Fornari L, et al. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 2002;143:2052-61
28. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 2004;11:430-7
29. Oviedo P, Hermenegildo C, Tarín JJ, Cano A. Raloxifene promotes prostacyclin release in human endothelial cells role of COX-1 and COX-2. Fertil Steril 2005;83:1822-9
30. Patterson AJ, Henrie-Olson J, Brenner R. Vasoregulation at the molecular level: a role for the beta1 subunit of the calcium-activated potassium (BK) channel. Trends Cardiovasc Med 2002;12:78-82
31. Díaz M. Triphenylethylene antiestrogen-induced acute relaxation of mouse duodenal muscle. Possible involvement of calcium channels. Eur J Pharmacol 2002;445:257-66
32. 2+ channels. Stroke 2004;35:1709-14
33. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003;59:883-92
34. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8
35. Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H. Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002;91:13-21
36. Wiseman H, Quinn P, Halliwell B. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions? FEBS Lett 1993;330:53-6
37. Resch U, Mellauner V, Budinsky A, Sinzinger H. Inhibition of low-density lipoprotein and high-density lipoprotein oxidation by raloxifene. J Womens Health (Larchmt) 2004;13:404-11
38. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996;126:65-75
39. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003;10:142-6
40. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068). Menopause 2002;9:430-5
41. Baumer AT, Wassmann S, Ahlbory K, et al. Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001;134:579-84
42. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 2002;434:141-9
43. Christopher TA, Lopez BL, Stillwagon JC, et al. Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats. Eur J Pharmacol 2002;446:139-43
44. Gonzalez-Perez J, Crespo MJ. Chronic effects of toremifene on the vasculature of menopause-induced rats. Vascul Pharmacol 2003;40:261-8
45. Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A. Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen. Br J Pharmacol 2003;140:1187-92
46. Tatchum-Talom R, Martel C, Labrie F, Marette A. Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res 2003;57:535-43
47. Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide- and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 2000;295:519-23
48. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 2001;38:657-65
49. Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Bryant HU, et al. The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther 2000;23:175-9
50. Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002;105:2083-91
51. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 1998;32:39-45
52. Takahashi K, Ohmichi M, Yoshida M, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 2003;178:319-29
53. Mori-Abe A, Tsutsumi S, Takahashi K, et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 2003;178:417-26
54. Dubey RK, Tyurina YY, Tyurin VA, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 1999;84:229-39
55. Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997;95:1542-8
56. Selzman CH, Turner AS, Gaynor JS, Miller SA, Monnet E, Harken AH. Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene. Arch Surg 2002;137:333-6
57. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964-9
58. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Knadler MP, Christiansen C. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol (Oxf) 2000;52:225-33
59. Bjarnason NH, Haarbo J, Byrjalsen I, Alexandersen P, Kauffman RF, Christiansen C. Raloxifene and estrogen reduces progression of advanced atherosclerosis - a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis 2001;154:97-102
60. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6
61. Yue TL, Vickery-Clark L, Louden CS, et al. Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 2000;102(Suppl 3):281-8
62. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33
63. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
64. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51
65. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000;63:225-34
66. Herrington DM, Pusser BE, Riley WA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000;20:1606-12
67. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90
68. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
69. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5
70. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004;164:871-9
71. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifentreatment after breast cancer surgery. Endocr J 1997;44:745-9
72. Kanel KT, Wolmark N, Thompson PD. Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 1997;337:281
73. Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001;39:71-7
74. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003;10:440-7
75. Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, van der Mooren MJ. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril 2004;82:1540-9
76. 2α-isoprostane levels in postmenopausal women. Fertil Steril 2005;84:1789-92
77. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endotheliumdependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-19
78. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:2135-40
79. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003;188:304-9
80. Ceresini G, Marchini L, Rebecchi I, et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 2003;167:121-7
81. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003;42:698-704
82. Koh KK, Bui MN, Mincemoyer R, Cannon RO 3rd. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-7
83. Blum A, Schenke WH, Hathaway L, et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 2000;86:892-5
84. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003;17:319-23
85. Simoncini T, De Caterina R, Genazzani AR. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 1999;84:815-18
86. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-22
87. Simon T, Boutouyrie P, Simon JM, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation 2002;106:2925-9
88. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004;147:1093-9
89. Orbe J, Fernandez L, Rodriguez JA, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003;170:269-76
90. Kong YZ, Yu X, Tang JJ, et al. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 2005;178:207-15
91. Kong YZ, Huang XR, Ouyang X, et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 2005;65:272-82
92. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-802
93. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO 3rd, Wahl LM. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001;21:1265-8
94. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8
95. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51
96. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-66
97. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63-8
98. Elhage R, Clamens S, Besnard S, et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001;156:315-20
99. Seli E, Pehlivan T, Selam B, Garcia-Velasco JA, Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril 2002;77:542-7
100. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-18
101. Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255-61
102. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-8
103. Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6097-9
104. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-9
105. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001;184:350-3
106. Smolders RG, Vogelvang TE, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41:105-14
107. Miller AP, Chen YF, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003;42:657-63
108. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999;82:997-1004
109. Bar J, Tepper R, Fuchs J, Pardo J, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993;81:261-4
110. Nakano Y, Oshima T, Matsuura H, Kajiyama G, Kambe M. Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol 1998;18:961-7
111. Chen FPL, Lee N, Wang CH, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267-73
112. Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000;84:695-700
113. García-Martínez MC, Labiós M, Hermenegildo C, Tarín JJ, O'Connor E, Cano A. The effect of hormone replacement therapy on Ca2+ mobilization and P-selectin (CD62P) expression in platelets examined under flow cytometry. Blood Coagul Fibrinolysis 2004;15:1-8
114. Boudoulas KD, Montague CR, Goldschmidt-Clermont PJ, Cooke GE. Estradiol increases platelet aggregation in Pl(A1/A1) individuals. Am Heart J 2006;152:136-9
115. Jayachandran M, Mukherjee R, Steinkamp T, et al. Differential effects of 17{beta}-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am J Physiol Heart Circ Physiol 2005;288:H2355-62
116. Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res 1994;74:577-94
117. Miller ME, Thorpe SL, Dores GM. Influence of hormones on platelet intracellular calcium. Thromb Res 1995;77:515-30
118. de Valk-de Roo GW, Stehouwer CD, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999;19:2993-3000
119. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001;93:16-21
120. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:1-2
121. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17